

Part B Immunosuppressive Drug benefit (PBID)

Numerical Ranking	2
Priority Ranking	High
Jira Feature ID	EQRS-164 - Part B Immunosuppressive Drug benefit (PBID) FUNNEL
SMT Owner	seema sreenivas
PdM Owner	Scott Laughlin
Product Owner	Michael Kennedy
Shallow Dive Scheduled	N/A
Deep Dive Scheduled	N/A
Size By Iteration: Small (1-2), Medium (2-3), Large (3-5), XL (6+)	
HCD	Yes
EDI Facing?	Yes

Business Objective

Extends immunosuppressive drug coverage for Medicare kidney transplant recipients beyond the current law 36-month limit following a transplant by providing immunosuppressive drug coverage under Medicare Part B for these individuals.

Business Description

We need to communicate between EDB, EQRS, SSA those benefits that would be terminated and those that would be extended, and design the systems and tools to support this new Medicare coverage.

Benefit Hypotheses

Individuals for whom Medicare coverage has already ended, or will end, **36 months after receiving a kidney transplant would be eligible for the immunosuppressive coverage** if they are not enrolled in certain other types of coverage. Coverage for these individuals would begin no earlier than January 1, 2023. This provision reflects a President's Budget Proposal policy for FY 2021.

Acceptance Criteria

Acceptance Criteria	Notes/Questions	Team(s) Involved
Starting September 2022, adjust routine terminations scheduler from 36 to 33 months after a successful transplant	How will the ESRD Networks review of terminations be impacted?	ESRD Networks; Gladidata ?

Assumptions

CMS is responsible for determining when entitlement under the ESRD provisions must be terminated. CMS controls the ESRD enrollment record until the termination date matures. Each month, **CMS provides a termination file to SSA's T2R system for those records on which a current termination is appropriate.**

Dependencies

Dependency	Outgoing Team(s)	Receiving Team(s)	Date Needed	Date Completed	Notes

Notes

• Coverage starts January 2023, as follows:

- o People whose 36-month coverage period ends before January 2023 can enroll starting in October 2022 and their coverage will start the later of January 2023 or the month after they enroll; and
- o People whose 36-month coverage period ends January 2023 or later will be automatically enrolled.

Additional Resources

<https://www.congress.gov/bill/116th-congress/house-bill/5534/text?q=%7B%22search%22%3A%5B%22HR5534%22%5D%7D&r=1&s=1>

CAA PBID Timeline (last updated 1/14/2022)



Draft CAA Sec 402 Timeline.pdf

The content below was pulled from <https://confluenceent.cms.gov/pages/viewpage.action?pageId=233823089> on 5/11/2022:

- SSA sends a new Basis Code = "I" for Special Part B Entitlements on the EDB CER file.
- Individuals whose 36-month coverage period ends before January 2023 can enroll starting in October 2022 and their coverage will start the later of January 2023 or the month after they enroll and attest that they don't have other coverage. **(Informational/Assumption - SSA to handle this rule).**
- If a beneficiary turns in the attestation after their ESRD coverage ends, their new PBID benefit would start the first of the month after they submit the attestation. **(Informational/Assumption - SSA to handle this rule).**
- This limited Part B benefit would only apply to immunosuppressive drug coverage and no other Part B service, (i.e. it does not cover any related physician services or lab tests). Ensure enrollments for coverage due to PBID do not include Part A or regular Part B.
- EDB to store the new Basis Code of "I" as **Enrollment Reason Code = "P"** into CME_SSA_PART B_Entitlement Table so that the system can accept, update, or withdraw/terminate new Part B data from SSA for the Part B Immunosuppressive Drug benefit.